R1	Has_index Arg1:T9 Arg2:T10	
*	OR T5 T8
R2	Subsumes Arg1:T5 Arg2:T6	
R3	Subsumes Arg1:T5 Arg2:T7	
R4	Subsumes Arg1:T5 Arg2:T9	
R5	Has_index Arg1:T14 Arg2:T15	
R6	Has_temporal Arg1:T13 Arg2:T14	
*	OR T18 T19
R7	Subsumes Arg1:T20 Arg2:T21	
R8	Subsumes Arg1:T22 Arg2:T23	
*	OR T20 T22
T1	Non-query-able 0 202	Patient has been permanently discontinued from pasireotide study treatment in the parent study due to unacceptable toxicity, non-compliance to study procedures, withdrawal of consent or any other reason
T2	Competing_trial 204 457	Patient has participated in a Novartis sponsored combination trial where pasireotide was dispensed in combination with another study medication and is still receiving combination therapy. (only patients receiving pasireotide monotherapy can be included)
T3	Pregnancy_considerations 463 650	nant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test
T4	Pregnancy_considerations 652 891	Total abstinence (when this is in line with the preferred and usual lifestyle of the subject. Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception
T5	Procedure 893 913	Female sterilization
T6	Procedure 933 955	bilateral oophorectomy
T7	Procedure 972 984	hysterectomy
T8	Procedure 989 1003	tubal ligation
T9	Temporal 1004 1052	at least six weeks before taking study treatment
T10	Reference_point 1030 1052	taking study treatment
T12	Non-query-able 1054 1188	In case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment
T13	Procedure 1190 1208	Male sterilization
T14	Temporal 1210 1246	at least 6 months prior to screening
T15	Reference_point 1237 1246	screening
T16	Non-query-able 1249 1355	For female subjects on the study the vasectomized male partner should be the sole partner for that subject
T17	Non-query-able 1358 1516	Use of oral, injected or implanted hormonal methods of contraception or other forms of hormonal contraception that have comparable efficacy (failure rate <1%)
T18	Procedure 1530 1550	hormone vaginal ring
T19	Procedure 1554 1587	transdermal hormone contraception
T20	Device 1605 1624	intrauterine device
T21	Device 1626 1629	IUD
T22	Device 1634 1653	intrauterine system
T23	Device 1655 1658	IUS
T24	Procedure 1680 1693	contraception
T25	Device 1695 1701	Condom
T26	Device 1705 1728	Occlusive cap diaphragm
T27	Device 1741 1751	vault caps
T28	Device 1732 1740;1747 1751	cervical caps
T29	Procedure 1758 1774	spermicidal foam
T30	Non-query-able 1661 1949	Barrier methods of contraception: Condom or Occlusive cap diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/vaginal suppository In case of use of oral contraception women should have been stable on the same pill for a minimum of 3 months before taking study treatment
T31	Non-query-able 1951 2702	Sexually active males unless they use a condom during intercourse while taking drug and for 1 months after pasireotide s.c. last dose and 3 months after pasireotide LAR last dose and should not father a child in this period. A condom is required to be used also by vasectomized men in order to prevent delivery of the drug via seminal fluid If a study patient or partner becomes pregnant or suspects being pregnant during the study or within 1 month after the final dose of pasireotide s.c. or 3 months after the final dose of pasireotide LAR, the Study Doctor needs to be informed immediately and ongoing study treatment with pasireotide has to be stopped immediately For patients taking pasireotide LAR, the future dose injections will be cancelled.
